In a significant advancement for Alzheimer’s disease (AD) research, scientists have developed an innovative multi-component self-assembling peptide-based hydrogel scaffold. The study published in Acta Biomaterialia offers a promising path to better understand the complex neurodegenerative condition by more accurately mimicking the amyloid-beta (Aβ) microenvironment that characterizes AD.
AD, known for its intricate pathology, has long challenged researchers. Traditional two-dimensional (2D) in vitro models fall short in replicating the true complexity of the brain’s extracellular matrix (ECM) and the role of amyloid structures. This limitation has spurred a shift towards three-dimensional (3D) in vitro disease modeling, which provides a more realistic platform for studying disease mechanisms.
The newly proposed hydrogel, named Col-HAMA-FF, is designed to replicate the amyloid-β microenvironment. Characterization of Col-HAMA-FF reveals the formation of β-sheet structures due to the self-assembling properties of phenylalanine (Phe, F) through π-π stacking of residues. This structural mimicry of amyloid-β protein nanostructures marks a significant step forward in creating more accurate disease models.
In their study, researchers compared the effects of the amyloid-β-mimicking hydrogel with a natural brain matrix (Col-HAMA) on healthy neuronal progenitor cells (NPCs). The results were strikink. NPCs cultured in the amyloid-like matrix exhibited higher levels of neuroinflammation and apoptosis markers compared to those in the natural brain matrix. These findings provide crucial insights into the impact of amyloid-like structures on NPC phenotypes and behaviors, offering a clearer picture of AD pathology.
Amyloid-beta (Aβ) is a peptide of 4 kDa in size, derived from the amyloid precursor protein (APP) through proteolytic processing. Aβ can aggregate to form plaques, which are a hallmark of AD pathology. These aggregates are believed to contribute to the neurodegenerative processes seen in AD by disrupting cell function, inducing oxidative stress, and triggering inflammatory responses in the brain. The accumulation and deposition of Aβ plaques are considered key events in the development and progression of Alzheimer’s disease.
This pioneering work lays the groundwork for future investigations into the mechanisms of AD and the testing of potential therapeutic drugs. By engineering hydrogels that closely replicate both the natural ECM of the brain and the amyloid-like microenvironment, researchers have opened new avenues for studying AD in a more realistic context.
These hydrogels mimic the β-amyloid fibrils found in amyloid-β protein aggregates. The culture of neuronal progenitor cells within the amyloid-mimicking ECM scaffold has revealed significant effects on marker expressions related to inflammation and DNA damage. This foundational research offers a promising scaffold for future studies on AD mechanisms and drug testing, paving the way for more accurate and effective therapeutic interventions.
Reference.
- Mathes TG, Monirizad M, Ermis M, de Barros NR, Rodriguez M, Kraatz HB, et al. Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal progenitor cell phenotype. Acta Biomaterialia. 2024 Jul 15; 183:89–100.
- Walsh DM, Selkoe DJ. Amyloid β-protein and beyond: the path forward in Alzheimer’s disease. Current Opinion in Neurobiology. 2020 Apr 1; 61:116–24.
- Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. International Journal of Biological Macromolecules. 2021 Jan 15; 167:382–94.
- Ribeiro A, Balasubramanian S, Hughes D, Vargo S, Powell EM, Leach JB. β1-Integrin cytoskeletal signaling regulates sensory neuron response to matrix dimensionality. Neuroscience. 2013 Sep 17; 248:67–78.
- Mathuranath PS, George A, Ranjith N, Justus S, Kumar MS, Menon R, et al. Incidence of Alzheimer′s disease in India: A 10-year follow-up study. Neurology India. 2012 Dec;60(6):625.
- Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry. 2021 Oct;26(10):5481–503.
- Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid Beta in Aging and Alzheimer’s Disease. International Journal of Molecular Sciences. 2022 Jan;23(21):12924.